Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerGlobeNewsWire • 11/30/23
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial LaunchGlobeNewsWire • 11/28/23
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.Business Wire • 11/15/23
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechGlobeNewsWire • 11/15/23
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate UpdateGlobeNewsWire • 11/14/23
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive MedicineGlobeNewsWire • 10/04/23
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to ParticipateGlobeNewsWire • 09/27/23
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment SolutionGlobeNewsWire • 09/25/23
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth ControlGlobeNewsWire • 09/20/23
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate UpdateGlobeNewsWire • 08/10/23
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBlocGlobeNewsWire • 08/03/23
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth ControlGlobeNewsWire • 07/27/23
Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' NowZacks Investment Research • 07/03/23